Your browser doesn't support javascript.
loading
Biomarker context-of-use: how organizational design can impact the implementation of the appropriate biomarker assay strategy.
J Cowan, Kyra; Golob, Michaela; Goodman, Joanne; Laurén, Anna; Andersen, Lene; Decker, Philip De; Dejager, Lien; Fjording, Marianne Scheel; Groenen, Peter; Jasnowski, Renaud; Justies, Nicole; Kimberg, Matti; Kunz, Ulrich; Lawrence, James; Richter, Mario; Sordé, Laetitia; Trigt, Radboud van; Vermet, Laurent; Vitaliti, Alessandra; Wright, Michael; Timmerman, Philip.
Afiliación
  • J Cowan K; Merck KGaA, New Biological Entities Drug Metabolism & Pharmacokinetics, Darmstadt, 64293, Germany.
  • Golob M; Nuvisan GmbH, Bioanalysis, Neu-Ulm, 89231, Germany.
  • Goodman J; Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, CB21 6GH, UK.
  • Laurén A; Novo Nordisk A/S, Non-clinical & Clinical Assay Sciences, Global Discovery & Development Sciences, Global Drug Discovery, Maløv, DK-2760, Denmark.
  • Andersen L; Lundbeck A/S, Experimental Medicine & Clinical Development, Valby, DK-2500, Denmark representing Orphazyme A/S, Clinical Development, Copenhagen N, DK-2200, Denmark.
  • Decker P; Argenx BV, Bioanalytics, Zwijnaarde, 9052, Belgium.
  • Dejager L; UCB Pharma, Development Science, Translational Biomarkers & Bioanalysis, Chemin du Foriest, Braine-l'Alleud, B-1420, Belgium.
  • Fjording MS; BioAgilytix Labs, Lademannbogen 10, Hamburg, 22339, Germany.
  • Groenen P; Idorsia Pharmaceuticals Ltd., Translational Biomarkers, Allschwil, 4123, Switzerland.
  • Jasnowski R; Active Biomarkers, 60F Avenue Rockefeller, Lyon, 69008, France.
  • Justies N; Roche Innovation Center Basel, Roche Pharmaceutical Research & Early Development, Basel, 4070, Switzerland.
  • Kimberg M; Synexa Life Sciences BV, Leiden, 2333 CS, The Netherlands.
  • Kunz U; Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine & Clinical Pharmacology, Biberach an der Riss, 88397, Germany.
  • Lawrence J; F-star Therapeutics, Cambridge, CB22 3AT, UK.
  • Richter M; AbbVie Deutschland GmbH & Co KG, DMPK-BA, Knollstrasse, Ludwigshafen, 67061, Germany.
  • Sordé L; Sobi AG, Bioanalytical Sciences, Plan-les-Ouates, 1228, Switzerland.
  • Trigt RV; ICON Bioanalytical Laboratories, Assen, 9407 TK, The Netherlands.
  • Vermet L; Sanofi Research & Development, Translational Medicine & Early Development, Biomarkers & Clinical Bioanalysis, Montpellier, 34080, France.
  • Vitaliti A; Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, 4056, Switzerland.
  • Wright M; GlaxoSmithKline, Bioanalysis Immunogenicity & Biomarkers, Stevenage, SG1 2NY, UK.
  • Timmerman P; European Bioanalysis Forum, Brussels, 1000, Belgium.
Bioanalysis ; 14(13): 911-917, 2022 Jul.
Article en En | MEDLINE | ID: mdl-35904153
ABSTRACT
Since 2011, the European Bioanalysis Forum has been discussing the topic of context-of-use for biomarker assays, in support of a cross-industry implementation of its principles. The discussions have led to the acknowledgement of the challenges that we face as an industry in implementing these principles. In addition to scientific recommendations, the European Bioanalysis Forum has addressed these challenges by providing recommendations on organizational design, and what works in both sponsor and contract research organizations, to support and enable context-of-use across biomarker strategies. Here, we highlight the key considerations for organizational design to help ensure that biomarker assays are characterized and validated according to the right context-of-use, to ensure that the right decisions based on the biomarker data can be made during drug development.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Bioensayo Tipo de estudio: Prognostic_studies Idioma: En Revista: Bioanalysis Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Bioensayo Tipo de estudio: Prognostic_studies Idioma: En Revista: Bioanalysis Año: 2022 Tipo del documento: Article País de afiliación: Alemania